Allergy Therapeutics – argues “significant clinical progress”, so why the further share price fall?
By Steve Moore | Friday 15 July 2022
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Allergy Therapeutics (AGY) has issued a trading update for its year ended 30th June 2022 emphasising “effective cost controls implemented alongside the group's significant clinical progress” and “in 2023, sales are expected to return to their previous near double-digit growth levels”. So what of a current share price response to 17p, approaching 7% lower?
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism
Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.